	US 12,473,339 B2
	Acylated glucagon analogues
Ditte Riber, Brønshøj (DK); Jakob Lind Tolborg, Herlev (DK); Dieter Wolfgang Hamprecht, Pozzolengo (IT); and Wolfgang Rist, Ingelheim am Rhein (DE)
Assigned to Zealand Pharma A/S, Søborg (DK)
Filed by Zealand Pharma A/S, Søborg (DK)
Filed on Jan. 9, 2024, as Appl. No. 18/408,052.
Application 18/408,052 is a continuation of application No. 17/369,061, filed on Jul. 7, 2021, granted, now 11,884,713.
Application 17/369,061 is a continuation of application No. 16/569,381, filed on Sep. 12, 2019, granted, now 11,091,528, issued on Aug. 17, 2021.
Application 16/569,381 is a continuation of application No. 15/852,458, filed on Dec. 22, 2017, granted, now 10,457,714, issued on Oct. 29, 2019.
Application 15/852,458 is a continuation of application No. 14/517,497, filed on Oct. 17, 2014, granted, now 9,896,495, issued on Feb. 20, 2018.
Claims priority of provisional application 61/892,256, filed on Oct. 17, 2013.
Prior Publication US 2024/0141010 A1, May 2, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/26 (2006.01); A61K 31/137 (2006.01); A61K 31/155 (2006.01); A61K 31/198 (2006.01); A61K 31/485 (2006.01); A61K 31/7048 (2006.01); A61K 38/28 (2006.01); A61K 45/06 (2006.01); A61P 3/04 (2006.01); A61P 3/06 (2006.01); A61P 3/10 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 9/12 (2006.01); A61P 11/00 (2006.01); A61P 43/00 (2006.01); C07K 14/605 (2006.01)

CPC C07K 14/605 (2013.01) [A61K 31/137 (2013.01); A61K 31/155 (2013.01); A61K 31/198 (2013.01); A61K 31/485 (2013.01); A61K 31/7048 (2013.01); A61K 38/26 (2013.01); A61K 38/28 (2013.01); A61K 45/06 (2013.01)]

20 Claims

1. A method of preventing weight gain or promoting weight loss in an individual in need thereof, said method comprising administering a therapeutically effective amount of a compound which is H—H-Aib-QGTFTSDYSKYLDERAAKDFI-K([17-carboxy-heptadecanoyl]-isoGlu-GSGSGG)-WLESA-NH₂(SEQ ID NO: 60), or a pharmaceutically acceptable salt thereof, to the individual.